In its semiannual drug pricing forecast, healthcare performance company Vizient said that biosimilars will be a key part of combatting rising spending on drugs among its membership.
In its semiannual drug pricing forecast, healthcare performance company Vizient said that biosimilars will be a key part of combatting rising spending on drugs among its membership.
Vizient’s membership currently spends approximately $67 billion on drugs annually, and with a projected 4.28% of drug price inflation, these members are expected to spend another $3 billion annually, even before considering cost increases for new drugs or volume changes.
The top 5 drugs by total spending among Vizient’s membership are adalimumab, infliximab, rituximab, etanercept, and pegfilgrastim, all of which have FDA-approved biosimilars, although only infliximab and pegfilgrastim biosimilars are yet available in the US market. Among these drugs, adalimumab, etanercept, infliximab, and rituximab are all projected to have some of the largest increases in price over the coming year.
As patents for reference products begin to expire, and as more biosimilars are launching in the US market, Vizient says that adopting biosimilars is critical to “combat the costs of these therapies.” In the interest of fostering adoption, Vizient has convened a biosimilars task force to create resources that will help members evaluate biosimilars for formulary inclusion as soon as they launch.
The company has also established a resource webpage for its members that includes evidence-based clinical information on biosimilars, including a soon-to-be-launched financial evaluation tool that members will be able to use to assess the cost and reimbursement impact of adopting different biosimilar-related strategies.
Finally, Vizient says that the market for oncology biosimilars will be “the true test” of whether a biosimilars market in the United States can be sustained, and “it is critically important that we focus our attention on supporting biosimilar evaluation and uptake,” given that spending on rituximab, bevacizumab, trastuzumab, and pegfilgrastim alone account for approximately $14 billion in member spending each year.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.